Multiple sclerosis is a heterogeneous disease whose manifestations vary considerably from patient to patient and whose course appears, on the surface, unpredictable. Hence, it is crucial to identify ...
The leading candidate for the repair of the central nervous system in multiple sclerosis failed in a Phase II study, highlighting the complexity ahead for a burgeoning pipeline of academic-led ...
SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Clene, Inc. (Nasdaq: CLNN) and its subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to advancing therapies ...
Long term extension of the Phase 2 VISIONARY-MS clinical trial of CNM-Au8 demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original ...
Ari Green, MD, of the University of California, San Francisco, details the benefits of remyelination for patients with multiple sclerosis (MS), as well as the challenges faced when conducting ...
Please provide your email address to receive an email when new articles are posted on . Nearly all patients in the open-label extension of VISIONARY-MS showed MRI evidence of neuronal repair and ...
BUFFALO, N.Y. — Remyelination, the spontaneous regeneration of the fatty insulator in the brain that keeps neurons communicating, has long been seen as crucial to the next big advance in treating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results